A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

A Phase 3 Japanese Study of BMS-790052 Plus BMS-650032 Combination Therapy in Chronic Hepatitis C Genotype 1b Infected Subjects Who Are Non Response to Interferon Plus Ribavirin and Interferon Based Therapy Ineligible Naive/Intolerant

The purpose of this study is to assess the anti-viral activity of BMS-790052 and BMS-650032 combination therapy in Japanese subjects.

Inclusion Criteria:

• Chronic HCV-1b infected patient
• HCV RNA viral load of ≥ 100,000 IU/mL at screening
• Ages 20 to 75 years
• Non-responder to Interferon plus Ribavirin therapy
• Patient who has been excluded from interferon/ribavirin therapy or intolerant for Interferon/Ribavirin therapy

Exclusion Criteria:

Patients who have -

• Hepatocellular carcinoma
• Co-infection with Hepatitis B virus (HBV) or Human Immunodeficiency Virus (HIV)
• Severe or uncontrollable complication